Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality - Takeaways - MDSpire

Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

  • By

  • Joaquín Martínez-López

  • María-Victoria Mateos

  • Cristina Encinas

  • Anna Sureda

  • José Ángel Hernández-Rivas

  • Ana Lopez de la Guía

  • Diego Conde

  • Isabel Krsnik

  • Elena Prieto

  • Rosalía Riaza Grau

  • Mercedes Gironella

  • María Jesús Blanchard

  • Nerea Caminos

  • Carlos Fernández de Larrea

  • María Alicia Senin

  • Fernando Escalante

  • José Enrique de la Puerta

  • Eugenio Giménez

  • Pilar Martínez-Barranco

  • Juan José Mateos

  • Luis Felipe Casado

  • Joan Bladé

  • Juan José Lahuerta

  • Javier de la Cruz

  • Jesús San-Miguel

  • October 19, 2020

  • 0 min

Share

  • 1

    Multiple myeloma (MM) patients exhibit severely impaired humoral immunity, making them highly susceptible to infections, including SARS-CoV-2.

  • 2

    The study analyzed 216 hospitalized MM patients with confirmed SARS-CoV-2 infection to identify clinical characteristics and mortality factors.

  • 3

    MM treatments can induce cytopenia, increasing the risk of bacterial and viral infections, complicating COVID-19 outcomes.

  • 4

    The study compared outcomes of MM patients with a matched non-cancer cohort, providing insights into the impact of cancer on COVID-19 severity.

  • 5

    Findings highlight the need for specific data on MM patients during the COVID-19 pandemic to inform treatment and management strategies.

Original Source(s)

Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

  • by Joaquín Martínez-López, María-Victoria Mateos, Cristina Encinas, Anna Sureda, José Ángel Hernández-Rivas, Ana Lopez de la Guía, Diego Conde, Isabel Krsnik, Elena Prieto, Rosalía Riaza Grau, Mercedes Gironella, María Jesús Blanchard, Nerea Caminos, Carlos Fernández de Larrea, María Alicia Senin, Fernando Escalante, José Enrique de la Puerta, Eugenio Giménez, Pilar Martínez-Barranco, Juan José Mateos, Luis Felipe Casado, Joan Bladé, Juan José Lahuerta, Javier de la Cruz, Jesús San-Miguel

  • October 19, 2020

Related Content

Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

  • April 27, 2026

  • 6 min
Understanding the Role of Regulatory T Cells in the Immune Microenvironment of Multiple Myeloma and Its Clinical Implications